https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Overall, the progress in melanoma therapeutics and translational research will help to optimize treatment regimens to overcome resistance and develop robust biomarkers to guide clinical decision-making. During the Melanoma Bridge meeting (December 3rd-5th, 2020, Italy) we reviewed the currently approved systemic and local therapies for advanced melanoma and discussed novel biomarker strategies and advances in precision medicine. Cytomegalovirus (CMV) infection is one of the main driving forces of T-cell senescence in the ge
Curtir
Comentario
Compartilhar
